Review



human hla dra recombinant protein  (Cusabio)


Bioz Verified Symbol Cusabio is a verified supplier
Bioz Manufacturer Symbol Cusabio manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 92
      Buy from Supplier

    Structured Review

    Cusabio human hla dra recombinant protein
    Human Hla Dra Recombinant Protein, supplied by Cusabio, used in various techniques. Bioz Stars score: 92/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human hla dra recombinant protein/product/Cusabio
    Average 92 stars, based on 2 article reviews
    human hla dra recombinant protein - by Bioz Stars, 2026-02
    92/100 stars

    Images



    Similar Products

    human hla dra recombinant protein  (Cusabio)
    92
    Cusabio human hla dra recombinant protein
    Human Hla Dra Recombinant Protein, supplied by Cusabio, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human hla dra recombinant protein/product/Cusabio
    Average 92 stars, based on 1 article reviews
    human hla dra recombinant protein - by Bioz Stars, 2026-02
    92/100 stars
    		  Buy from Supplier
    human hla-dqb2 (hla class ii histocompatibility antigen, dq beta 2 chain) (eh9135)  (Wuhan Fine Biotech)
    90
    Wuhan Fine Biotech human hla-dqb2 (hla class ii histocompatibility antigen, dq beta 2 chain) (eh9135)
    Human Hla Dqb2 (Hla Class Ii Histocompatibility Antigen, Dq Beta 2 Chain) (Eh9135), supplied by Wuhan Fine Biotech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human hla-dqb2 (hla class ii histocompatibility antigen, dq beta 2 chain) (eh9135)/product/Wuhan Fine Biotech
    Average 90 stars, based on 1 article reviews
    human hla-dqb2 (hla class ii histocompatibility antigen, dq beta 2 chain) (eh9135) - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    human hla class ii histocompatibility antigen, dr alpha chain (hla-dra) elisa kit  (Cusabio)
    90
    Cusabio human hla class ii histocompatibility antigen, dr alpha chain (hla-dra) elisa kit
    Quantification of sHLA class I molecules in COVID-19 patients, SARS-CoV-2 convalescent individuals and healthy donors (A) Soluble HLA class I levels in the serum of COVID-19 (n = 31), Convalescent (n = 290) and Control donors (n = 80). See <xref ref-type=Figure S3 A for sHLA-DR. (B and C) Longitudinal follow-up analysis of sHLA class I levels in (B) convalescent individuals (n = 53) at different timepoints ( T1 , timepoint 1, 19 - 52 days after positive PCR; T2 , timepoint 2, 141 - 170 days after positive PCR) and (C) compared to healthy control donors ( Control , n = 80). (D) Soluble HLA class I levels in the serum of convalescents with ( persisting symptoms , n = 51) and without ( asymptomatic , n = 11) persistence of symptoms after SARS-CoV-2 infection compared to healthy control donors ( Control , n = 80). (E) Soluble HLA class I serum levels in COVID-19 patients with (n = 4) and without (n = 26) requirement for invasive ventilation. (F) Correlation analysis of sHLA class I levels to SARS-CoV-2-specific T cell response intensities in terms of calculated spot counts in ELISpot assays in convalescent individuals (n = 68). Linear regression line with 95% confidence level (dotted lines), Spearman’s rho (ρ) and p value. Each dot represents the sHLA class I serum level of one donor measured by enzyme-linked immunosorbent assay (ELISA). Boxes represent median and 25 th to 75 th percentiles, whiskers are minimum to maximum. Different symbols represent COVID-19-specific treatment (no treatment, remdesivir, dexamethasone, combined treatment with remdesivir and dexamethasone) for the COVID-19 cohort within three days before sample collection. (A, D) Kruskal-Wallis test, (B) Wilcoxon matched-pairs signed rank test, (C) Mann-Whitney U test comparing T1 or T2 to Control . " width="250" height="auto" />
    Human Hla Class Ii Histocompatibility Antigen, Dr Alpha Chain (Hla Dra) Elisa Kit, supplied by Cusabio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human hla class ii histocompatibility antigen, dr alpha chain (hla-dra) elisa kit/product/Cusabio
    Average 90 stars, based on 1 article reviews
    human hla class ii histocompatibility antigen, dr alpha chain (hla-dra) elisa kit - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    human hla class ii histocompatibility antigen  (Cusabio)
    93
    Cusabio human hla class ii histocompatibility antigen
    Quantification of sHLA class I molecules in COVID-19 patients, SARS-CoV-2 convalescent individuals and healthy donors (A) Soluble HLA class I levels in the serum of COVID-19 (n = 31), Convalescent (n = 290) and Control donors (n = 80). See <xref ref-type=Figure S3 A for sHLA-DR. (B and C) Longitudinal follow-up analysis of sHLA class I levels in (B) convalescent individuals (n = 53) at different timepoints ( T1 , timepoint 1, 19 - 52 days after positive PCR; T2 , timepoint 2, 141 - 170 days after positive PCR) and (C) compared to healthy control donors ( Control , n = 80). (D) Soluble HLA class I levels in the serum of convalescents with ( persisting symptoms , n = 51) and without ( asymptomatic , n = 11) persistence of symptoms after SARS-CoV-2 infection compared to healthy control donors ( Control , n = 80). (E) Soluble HLA class I serum levels in COVID-19 patients with (n = 4) and without (n = 26) requirement for invasive ventilation. (F) Correlation analysis of sHLA class I levels to SARS-CoV-2-specific T cell response intensities in terms of calculated spot counts in ELISpot assays in convalescent individuals (n = 68). Linear regression line with 95% confidence level (dotted lines), Spearman’s rho (ρ) and p value. Each dot represents the sHLA class I serum level of one donor measured by enzyme-linked immunosorbent assay (ELISA). Boxes represent median and 25 th to 75 th percentiles, whiskers are minimum to maximum. Different symbols represent COVID-19-specific treatment (no treatment, remdesivir, dexamethasone, combined treatment with remdesivir and dexamethasone) for the COVID-19 cohort within three days before sample collection. (A, D) Kruskal-Wallis test, (B) Wilcoxon matched-pairs signed rank test, (C) Mann-Whitney U test comparing T1 or T2 to Control . " width="250" height="auto" />
    Human Hla Class Ii Histocompatibility Antigen, supplied by Cusabio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human hla class ii histocompatibility antigen/product/Cusabio
    Average 93 stars, based on 1 article reviews
    human hla class ii histocompatibility antigen - by Bioz Stars, 2026-02
    93/100 stars
    		  Buy from Supplier
    csb el010497hu  (Cusabio)
    88
    Cusabio csb el010497hu
    Quantification of sHLA class I molecules in COVID-19 patients, SARS-CoV-2 convalescent individuals and healthy donors (A) Soluble HLA class I levels in the serum of COVID-19 (n = 31), Convalescent (n = 290) and Control donors (n = 80). See <xref ref-type=Figure S3 A for sHLA-DR. (B and C) Longitudinal follow-up analysis of sHLA class I levels in (B) convalescent individuals (n = 53) at different timepoints ( T1 , timepoint 1, 19 - 52 days after positive PCR; T2 , timepoint 2, 141 - 170 days after positive PCR) and (C) compared to healthy control donors ( Control , n = 80). (D) Soluble HLA class I levels in the serum of convalescents with ( persisting symptoms , n = 51) and without ( asymptomatic , n = 11) persistence of symptoms after SARS-CoV-2 infection compared to healthy control donors ( Control , n = 80). (E) Soluble HLA class I serum levels in COVID-19 patients with (n = 4) and without (n = 26) requirement for invasive ventilation. (F) Correlation analysis of sHLA class I levels to SARS-CoV-2-specific T cell response intensities in terms of calculated spot counts in ELISpot assays in convalescent individuals (n = 68). Linear regression line with 95% confidence level (dotted lines), Spearman’s rho (ρ) and p value. Each dot represents the sHLA class I serum level of one donor measured by enzyme-linked immunosorbent assay (ELISA). Boxes represent median and 25 th to 75 th percentiles, whiskers are minimum to maximum. Different symbols represent COVID-19-specific treatment (no treatment, remdesivir, dexamethasone, combined treatment with remdesivir and dexamethasone) for the COVID-19 cohort within three days before sample collection. (A, D) Kruskal-Wallis test, (B) Wilcoxon matched-pairs signed rank test, (C) Mann-Whitney U test comparing T1 or T2 to Control . " width="250" height="auto" />
    Csb El010497hu, supplied by Cusabio, used in various techniques. Bioz Stars score: 88/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/csb el010497hu/product/Cusabio
    Average 88 stars, based on 1 article reviews
    csb el010497hu - by Bioz Stars, 2026-02
    88/100 stars
    		  Buy from Supplier
    human leukocyte antigen d  (Cusabio)
    88
    Cusabio human leukocyte antigen d
    Quantification of sHLA class I molecules in COVID-19 patients, SARS-CoV-2 convalescent individuals and healthy donors (A) Soluble HLA class I levels in the serum of COVID-19 (n = 31), Convalescent (n = 290) and Control donors (n = 80). See <xref ref-type=Figure S3 A for sHLA-DR. (B and C) Longitudinal follow-up analysis of sHLA class I levels in (B) convalescent individuals (n = 53) at different timepoints ( T1 , timepoint 1, 19 - 52 days after positive PCR; T2 , timepoint 2, 141 - 170 days after positive PCR) and (C) compared to healthy control donors ( Control , n = 80). (D) Soluble HLA class I levels in the serum of convalescents with ( persisting symptoms , n = 51) and without ( asymptomatic , n = 11) persistence of symptoms after SARS-CoV-2 infection compared to healthy control donors ( Control , n = 80). (E) Soluble HLA class I serum levels in COVID-19 patients with (n = 4) and without (n = 26) requirement for invasive ventilation. (F) Correlation analysis of sHLA class I levels to SARS-CoV-2-specific T cell response intensities in terms of calculated spot counts in ELISpot assays in convalescent individuals (n = 68). Linear regression line with 95% confidence level (dotted lines), Spearman’s rho (ρ) and p value. Each dot represents the sHLA class I serum level of one donor measured by enzyme-linked immunosorbent assay (ELISA). Boxes represent median and 25 th to 75 th percentiles, whiskers are minimum to maximum. Different symbols represent COVID-19-specific treatment (no treatment, remdesivir, dexamethasone, combined treatment with remdesivir and dexamethasone) for the COVID-19 cohort within three days before sample collection. (A, D) Kruskal-Wallis test, (B) Wilcoxon matched-pairs signed rank test, (C) Mann-Whitney U test comparing T1 or T2 to Control . " width="250" height="auto" />
    Human Leukocyte Antigen D, supplied by Cusabio, used in various techniques. Bioz Stars score: 88/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human leukocyte antigen d/product/Cusabio
    Average 88 stars, based on 1 article reviews
    human leukocyte antigen d - by Bioz Stars, 2026-02
    88/100 stars
    		  Buy from Supplier

    Image Search Results


    Quantification of sHLA class I molecules in COVID-19 patients, SARS-CoV-2 convalescent individuals and healthy donors (A) Soluble HLA class I levels in the serum of COVID-19 (n = 31), Convalescent (n = 290) and Control donors (n = 80). See <xref ref-type=Figure S3 A for sHLA-DR. (B and C) Longitudinal follow-up analysis of sHLA class I levels in (B) convalescent individuals (n = 53) at different timepoints ( T1 , timepoint 1, 19 - 52 days after positive PCR; T2 , timepoint 2, 141 - 170 days after positive PCR) and (C) compared to healthy control donors ( Control , n = 80). (D) Soluble HLA class I levels in the serum of convalescents with ( persisting symptoms , n = 51) and without ( asymptomatic , n = 11) persistence of symptoms after SARS-CoV-2 infection compared to healthy control donors ( Control , n = 80). (E) Soluble HLA class I serum levels in COVID-19 patients with (n = 4) and without (n = 26) requirement for invasive ventilation. (F) Correlation analysis of sHLA class I levels to SARS-CoV-2-specific T cell response intensities in terms of calculated spot counts in ELISpot assays in convalescent individuals (n = 68). Linear regression line with 95% confidence level (dotted lines), Spearman’s rho (ρ) and p value. Each dot represents the sHLA class I serum level of one donor measured by enzyme-linked immunosorbent assay (ELISA). Boxes represent median and 25 th to 75 th percentiles, whiskers are minimum to maximum. Different symbols represent COVID-19-specific treatment (no treatment, remdesivir, dexamethasone, combined treatment with remdesivir and dexamethasone) for the COVID-19 cohort within three days before sample collection. (A, D) Kruskal-Wallis test, (B) Wilcoxon matched-pairs signed rank test, (C) Mann-Whitney U test comparing T1 or T2 to Control . " width="100%" height="100%">

    Journal: iScience

    Article Title: Increased soluble HLA in COVID-19 present a disease-related, diverse immunopeptidome associated with T cell immunity

    doi: 10.1016/j.isci.2022.105643

    Figure Lengend Snippet: Quantification of sHLA class I molecules in COVID-19 patients, SARS-CoV-2 convalescent individuals and healthy donors (A) Soluble HLA class I levels in the serum of COVID-19 (n = 31), Convalescent (n = 290) and Control donors (n = 80). See Figure S3 A for sHLA-DR. (B and C) Longitudinal follow-up analysis of sHLA class I levels in (B) convalescent individuals (n = 53) at different timepoints ( T1 , timepoint 1, 19 - 52 days after positive PCR; T2 , timepoint 2, 141 - 170 days after positive PCR) and (C) compared to healthy control donors ( Control , n = 80). (D) Soluble HLA class I levels in the serum of convalescents with ( persisting symptoms , n = 51) and without ( asymptomatic , n = 11) persistence of symptoms after SARS-CoV-2 infection compared to healthy control donors ( Control , n = 80). (E) Soluble HLA class I serum levels in COVID-19 patients with (n = 4) and without (n = 26) requirement for invasive ventilation. (F) Correlation analysis of sHLA class I levels to SARS-CoV-2-specific T cell response intensities in terms of calculated spot counts in ELISpot assays in convalescent individuals (n = 68). Linear regression line with 95% confidence level (dotted lines), Spearman’s rho (ρ) and p value. Each dot represents the sHLA class I serum level of one donor measured by enzyme-linked immunosorbent assay (ELISA). Boxes represent median and 25 th to 75 th percentiles, whiskers are minimum to maximum. Different symbols represent COVID-19-specific treatment (no treatment, remdesivir, dexamethasone, combined treatment with remdesivir and dexamethasone) for the COVID-19 cohort within three days before sample collection. (A, D) Kruskal-Wallis test, (B) Wilcoxon matched-pairs signed rank test, (C) Mann-Whitney U test comparing T1 or T2 to Control .

    Article Snippet: Human HLA Class II Histocompatibility Antigen, DR Alpha Chain (HLA-DRA) ELISA kit , Cusabio , Cat# CSB-EL010497HU.

    Techniques: Control, Infection, Enzyme-linked Immunospot, Enzyme-linked Immunosorbent Assay, MANN-WHITNEY

    Journal: iScience

    Article Title: Increased soluble HLA in COVID-19 present a disease-related, diverse immunopeptidome associated with T cell immunity

    doi: 10.1016/j.isci.2022.105643

    Figure Lengend Snippet:

    Article Snippet: Human HLA Class II Histocompatibility Antigen, DR Alpha Chain (HLA-DRA) ELISA kit , Cusabio , Cat# CSB-EL010497HU.

    Techniques: Recombinant, Enzyme-linked Immunosorbent Assay, Protease Inhibitor, Mass Spectrometry, Generated, Software